

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Prescribed list as of 1 February 2023
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Date decision made if different to date 'Ministerial Decision Summary' signed.	Select date.
Report and Supplemental Report Details	
Report Author	Senior Policy Officer
Date of Report	19/12/2022
Supplementary Report Title <i>(If applicable)</i>	Insert Supplemental Report Title.
Supplementary Report Author <i>(If applicable)</i>	Insert Official Title Only.
Date of Supplementary Report <i>(If applicable)</i>	Select Date of Supplemental Report.
Ministerial Decision Report: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.

Resource Implications	There are new financial and/or manpower implications. Further detail is included in the detail section of the report.
-----------------------	-----------------------------------------------------------------------------------------------------------------------

## Introduction

Items of Pharmaceutical benefit, which can be prescribed in the community by approved prescribers, are maintained on a Prescribed list. Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, the Minister for Social Security may amend the Prescribed List, having consulted with the Pharmaceutical Benefit Advisory Committee.

## Recommendation

Other

1. Only insert text if 'Other' selected above.

### 1. Items to be added to the prescribed list.

- Quetiapine modified-release tablets 50mg, 150mg, 200mg, 300mg, 400mg, 600mg
- Liothyronine capsules 5mcg, 10mcg, 20mcg
- Otigo ear drops (Phenazone 40mg / lidocaine hydrochloride 10mg)
- Testosterone (Testogel) 40.5mg/2.5g gel sachets – new strength
- Amorolfine 5% medicated nail lacquer

### 2. Items to be removed from the Prescribed List from 1 May 2023

The Committee recommended removal of the following products from the Prescribed List that are now discontinued. Alternative products are available on the List where necessary.

- Acebutolol 100mg & 200mg capsules
- Selenium sulfide 2.5% shampoo
- Insulatard isophane human 100units/ml suspension for injection 5ml vial
- Insulin isophane biphasic human 10/90 100units/ml suspension for injection 1.5ml cartridges / 3mL cartridges / 3mL pre-filled disposable device
- Insulin isophane biphasic human 15/85 100units/ml suspension for injection 3ml cartridges / 3mL pre-filled disposable devices / 5mL vials
- Insulin isophane biphasic human 20/80 100units/ml suspension for injection 1.5mL cartridges / 3ml cartridges / 3mL pre-filled disposable devices
- Insulin isophane biphasic human 25/75 100units/ml suspension for injection 5ml vials
- Insulin isophane biphasic human 30/70 100units/ml suspension for injection 1.5ml cartridges
- Insulin isophane biphasic human 40/60 100units/ml suspension for injection 1.5ml cartridges / 3mL cartridges / 3mL pre-filled disposable devices
- Insulin isophane biphasic human 50/50 100units/ml suspension for injection 1.5ml cartridges / 5mL vial / 10mL vial / 3mL pre-filled disposable devices
- Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 1.5ml cartridges

## Detail

The Minister decided to make amendments to the Prescribed List with effect from 1 February 2023 following recommendations made by the Pharmaceutical Benefit Advisory Committee on 10 November 2022.

The estimated cost impact of the recommended changes is an overall increase in net annual expenditure of £12,000 pa.